HCPCS A9586: Florbetapir F18 Diagnostic PET Dose, Up to 10 mCi

HCPCS Level II code A9586 covers administration of florbetapir F18 for diagnostic PET imaging, billed per study dose up to 10 millicuries. This radiopharmaceutical is used in amyloid PET scans to detect beta-amyloid plaque in the brain, a clinically relevant tool in evaluating patients with cognitive impairment and suspected Alzheimer disease pathology. Nationally, PET radiotracers like florbetapir influence utilization patterns, imaging center workflows, and payer coverage policies due to their specialized supply, handling, and interpretation requirements.

Key payers in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what A9586 represents, typical sites of service, and the clinical context for use. The publication also summarizes benchmark elements and policy considerations relevant to reimbursement and coverage determinations for radiopharmaceuticals, along with practical coding and billing context for service lines that manage PET imaging. Data not available in the input are noted where applicable.

Customize your policy alerts

Sign up for hcpcs A9586 policy alerts

Get alerted when payer policies referencing A9586 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

HCPCS Level II code A9586 describes florbetapir F18 provided for diagnostic imaging, billed per study dose, up to 10 millicuries. This service represents administration of a radiopharmaceutical tracer used in PET imaging to evaluate beta-amyloid plaque in the brain for diagnostic purposes.

Service Type: Radiopharmaceutical diagnostic imaging study (PET tracer administration)

Typical Site of Service: Hospital outpatient department or ambulatory imaging center

Explore openpayer tools

View all tools

HCPCS A9586: Florbetapir F18 Diagnostic PET Dose, Up to 10 mCi

Customize your policy alerts

Sign up for hcpcs A9586 policy alerts

Get alerted when payer policies referencing A9586 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Service Type: Radiopharmaceutical diagnostic imaging study (PET tracer administration)

Typical Site of Service: Hospital outpatient department or ambulatory imaging center

Clinical & Coding Specifications

Clinical Context

A typical patient is an older adult referred by a neurologist for evaluation of progressive cognitive decline, memory loss, or suspected Alzheimer disease when amyloid imaging will affect clinical management. The patient arrives at an outpatient nuclear medicine or PET imaging center. After registration and review of indications, an IV line is placed and a measured study dose of Florbetapir F18 (up to 10 millicuries, billed as A9586) is administered. A 20–30 minute uptake period follows per local protocol, then the patient is positioned in the PET scanner for acquisition of images of the brain. Images are processed, interpreted by a board-certified nuclear medicine physician or neuroradiologist, and a report documenting presence or absence of cortical amyloid deposition is generated. Results are communicated to the referring clinician for integration into diagnosis and care planning. Typical site of service is an outpatient imaging center or hospital outpatient department. Typical modifiers applied depend on professional vs technical components, unusual procedural circumstances, or payer-specific reporting requirements (for example, professional component modifier 26, technical component modifier TC, or modifier for reduced services 52).

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G30.9`	Alzheimer disease, unspecified	Common indication for amyloid PET to assess cerebral amyloid deposition when diagnosis is uncertain.
`F02.80`	Dementia in other disease classified elsewhere without behavioral disturbance	Used when dementia is present and amyloid imaging is performed to clarify etiology.
`F03.90`	Unspecified dementia, unspecified	Frequently listed when cognitive decline prompts further evaluation including amyloid PET.
`R41.3`	Other amnesia	Memory impairment investigations may include amyloid PET if Alzheimer disease is suspected.
`R41.81`	Age-related cognitive decline	Used in older adults undergoing imaging to distinguish neurodegenerative causes.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`78608`	Positron emission tomography (PET) imaging, brain, metabolic/biochemical assessment	Commonly used for the PET acquisition component when billing PET study services of the brain alongside the radiopharmaceutical.
`78811`	Positron emission tomography (PET) with concurrently acquired CT for attenuation correction and anatomical localization; brain	Used when PET is combined with CT for attenuation correction and anatomic correlation during amyloid imaging.
`0354T`	PET imaging, diagnostic, amyloid plaque in brain, florbetapir F18; interpretation and report	Category III CPT code that may be used for reporting the amyloid PET interpretation and report when applicable alongside radiopharmaceutical billing.
`G0252`	Technetium Tc 99m exam (placeholder) (not directly related)	Data not available in the input or not directly applicable; included codes above are the primary relevant CPTs.

Related Modifiers

8 rows

Modifier
26
52
53
59
76
62
78
80

Related Provider Taxonomies

8 rows

Taxonomy Code
208000000X
2084P0800X
207RH0000X
363L00000X
367A00000X
2278P1005X
385HR2065X
347C00000X

Related Codes

HCPCS-A9150-NON-PRESCRIPTION-DRUGS

HCPCS Level II A9150: Non-Prescription Drugs

HCPCS-A9152-SINGLE-ORAL-VITAMIN-MINERAL-DOSE

HCPCS A9152: Single Oral Vitamin/Mineral/Trace Element, Per Dose

HCPCS-A9153-MULTIVITAMIN-ORAL-PER-DOSE

HCPCS A9153: Multiple Vitamins, Oral, Per Dose

HCPCS-A9154-ARTIFICIAL-SALIVA-1ML

HCPCS Level II A9154: Artificial Saliva, 1 ml

HCPCS-A9155-ARTIFICIAL-SALIVA-30ML

HCPCS A9155: Artificial Saliva, 30 ml

HCPCS-A9156-ORAL-MUCOADHESIVE-PER-1ML

HCPCS A9156: Oral Mucoadhesive, Per 1 ml

HCPCS-A9180-PEDICULOSIS-TOPICAL-TREATMENT-PATIENT-ADMINISTRATION

HCPCS Level II A9180: Pediculosis Topical Treatment for Patient/Caretaker

HCPCS-A9268-PROGRAMMER-TRANSIENT-INGESTED-CAPSULE

HCPCS A9268: Programmer for Transient Orally Ingested Capsule

HCPCS-A9269-PROGRAMMABLE-TRANSIENT-ORAL-CAPSULE

HCPCS A9269: Programmable Transient Orally Ingested Capsule, Monthly

HCPCS-A9270-NON-COVERED-ITEM-OR-SERVICE

HCPCS Level II A9270: Non-covered Item or Service

Showing 1–10 of 138

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical & Coding Specifications

Clinical Context

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G30.9`	Alzheimer disease, unspecified	Common indication for amyloid PET to assess cerebral amyloid deposition when diagnosis is uncertain.
`F02.80`	Dementia in other disease classified elsewhere without behavioral disturbance	Used when dementia is present and amyloid imaging is performed to clarify etiology.
`F03.90`	Unspecified dementia, unspecified	Frequently listed when cognitive decline prompts further evaluation including amyloid PET.
`R41.3`	Other amnesia	Memory impairment investigations may include amyloid PET if Alzheimer disease is suspected.
`R41.81`	Age-related cognitive decline	Used in older adults undergoing imaging to distinguish neurodegenerative causes.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`78608`	Positron emission tomography (PET) imaging, brain, metabolic/biochemical assessment	Commonly used for the PET acquisition component when billing PET study services of the brain alongside the radiopharmaceutical.
`78811`	Positron emission tomography (PET) with concurrently acquired CT for attenuation correction and anatomical localization; brain	Used when PET is combined with CT for attenuation correction and anatomic correlation during amyloid imaging.
`0354T`	PET imaging, diagnostic, amyloid plaque in brain, florbetapir F18; interpretation and report	Category III CPT code that may be used for reporting the amyloid PET interpretation and report when applicable alongside radiopharmaceutical billing.
`G0252`	Technetium Tc 99m exam (placeholder) (not directly related)	Data not available in the input or not directly applicable; included codes above are the primary relevant CPTs.

Related Modifiers

8 rows

Modifier
26
52
53
59
76
62
78
80

Related Provider Taxonomies

8 rows

Taxonomy Code
208000000X
2084P0800X
207RH0000X
363L00000X
367A00000X
2278P1005X
385HR2065X
347C00000X

Related Codes

HCPCS-A9150-NON-PRESCRIPTION-DRUGS

HCPCS Level II A9150: Non-Prescription Drugs

HCPCS-A9152-SINGLE-ORAL-VITAMIN-MINERAL-DOSE

HCPCS A9152: Single Oral Vitamin/Mineral/Trace Element, Per Dose

HCPCS-A9153-MULTIVITAMIN-ORAL-PER-DOSE

HCPCS A9153: Multiple Vitamins, Oral, Per Dose

HCPCS-A9154-ARTIFICIAL-SALIVA-1ML

HCPCS Level II A9154: Artificial Saliva, 1 ml

HCPCS-A9155-ARTIFICIAL-SALIVA-30ML

HCPCS A9155: Artificial Saliva, 30 ml

HCPCS-A9156-ORAL-MUCOADHESIVE-PER-1ML

HCPCS A9156: Oral Mucoadhesive, Per 1 ml

HCPCS-A9180-PEDICULOSIS-TOPICAL-TREATMENT-PATIENT-ADMINISTRATION

HCPCS Level II A9180: Pediculosis Topical Treatment for Patient/Caretaker

HCPCS-A9268-PROGRAMMER-TRANSIENT-INGESTED-CAPSULE

HCPCS A9268: Programmer for Transient Orally Ingested Capsule

HCPCS-A9269-PROGRAMMABLE-TRANSIENT-ORAL-CAPSULE

HCPCS A9269: Programmable Transient Orally Ingested Capsule, Monthly

HCPCS-A9270-NON-COVERED-ITEM-OR-SERVICE

HCPCS Level II A9270: Non-covered Item or Service

Showing 1–10 of 138

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.